Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 26;35(9):1273-1278.
doi: 10.1111/dme.13693. Online ahead of print.

The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis

S Heller  1 , K Bowering  2 , P Raskin  3 , A Liebl  4 , K Buchholtz  5 , A Gorst-Rasmussen  5 , T R Pieber  6
Affiliations

The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis

S Heller et al. Diabet Med. .

Abstract

Aims: To investigate the impact of baseline 1,5-anhydroglucitol on the treatment effect of basal-bolus therapy in people with Type 2 diabetes.

Methods: Post hoc analysis of onset 3, an 18-week, randomized, phase 3 trial evaluating the efficacy and safety of fast-acting insulin aspart in basal-bolus therapy (n = 116) vs. basal insulin-only therapy (n = 120) in people with Type 2 diabetes. The estimated treatment difference in change from baseline in HbA1c was investigated for different cut-off values of baseline 1,5-anhydroglucitol (2, 3, 4, 5 and 6 μg/ml).

Results: The estimated treatment difference in change from baseline in HbA1c between basal-bolus therapy and basal insulin-only therapy was statistically significantly greater in participants with baseline 1,5-anhydroglucitol ≤3 μg/ml (n = 34) vs. >3 μg/ml (n = 198) [estimated treatment difference (95% CI): -1.53% (-2.12; -0.94) vs. -0.82% (-1.07; -0.57); P-value for interaction = 0.03]. The estimated treatment difference became more pronounced when comparing participants with 1,5-anhydroglucitol ≤2 μg/ml (n = 15) vs. >2 μg/ml (n = 217) [estimated treatment difference (95% CI): -2.26% (-3.15; -1.36) vs. -0.85% (-1.08; -0.62); P-value for interaction = 0.003]. For cut-off values ≥4 μg/ml, estimated treatment differences were numerically greater below the cut-off compared with above, although the interaction terms were not statistically significant.

Conclusion: This analysis indicates that people with Type 2 diabetes with low 1,5-anhydroglucitol have an added treatment benefit with basal-bolus therapy compared with people with higher 1,5-anhydroglucitol. Further research is needed to clarify any clinical utility of these findings. Clinical Trials Registry No: NCT01850615.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scatter plot of change from baseline in HbA1c after 18 weeks of randomized treatment against baseline 1,5‐AG. Penalized B‐spline scatter plot smoothing is used to depict the association between change from baseline in HbA1c and baseline 1,5‐AG. 1,5‐AG, 1,5‐anhydroglucitol; faster aspart, fast‐acting insulin aspart.
Figure 2
Figure 2
Estimated treatment difference in change from baseline in HbA1c above and below different 1,5‐AG cut‐off values. Change from baseline in HbA1c was analysed using an MMRM. The model included a treatment‐by‐subgroup interaction, alongside main effects of treatment, subgroup (above/below cut‐off value), region and strata, with baseline HbA1c and baseline 1,5‐AG as covariates. P‐values for the interaction term were used to evaluate if the ETD was different above vs. below the cut‐off values. Only participants with post‐baseline HbA1c data contributed to the MMRM analysis (n = 232). 1,5‐AG, 1,5‐anhydroglucitol; CI, confidence interval; ETD, estimated treatment difference; MMRM, mixed‐effects model for repeated measures; n, number of participants contributing to the analysis.
See this image and copyright information in PMC

References

    1. American Diabetes Association. Diabetes Care 2017; 40: S1–S135. - PubMed
    1. Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J et al Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007; 77: 280–285. - PubMed
    1. Dungan KM. 1,5‐anhydroglucitol (GlycoMark) as a marker of short‐term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008; 8: 9–19. - PubMed
    1. McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T et al U.S. trial of the GlycoMark assay. Circulating 1,5‐anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 2004; 27: 1859–1865. - PubMed
    1. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5‐anhydroglucitol (GlycoMark): a short‐term glycemic marker. Diabetes Technol Ther 2003; 5: 355–363. - PubMed

Associated data